The 10 essential questions regarding lipoprotein(a).

IF 3 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Current Opinion in Clinical Nutrition and Metabolic Care Pub Date : 2024-03-01 Epub Date: 2023-11-14 DOI:10.1097/MCO.0000000000000994

Karam M Kostner, Gerhard M Kostner

{"title":"The 10 essential questions regarding lipoprotein(a).","authors":"Karam M Kostner, Gerhard M Kostner","doi":"10.1097/MCO.0000000000000994","DOIUrl":null,"url":null,"abstract":"Purpose of review: Lp(a) is one of the most atherogenic lipoproteins, and significant progress has been made to understand its pathophysiology over the last 20 years. There are now selective therapies in late-stage clinical trials to lower Lp(a). Yet there are many outstanding questions about Lp(a). This review outlines 10 of the most burning questions and tries to answer some of them.Recent findings: Antisense oligonucleotide (ASO) treatment is currently the most advanced therapy to lower plasma Lp(a) by 60-80%. There are, however, also two small molecule medications in early stage of development with similar efficacy.Summary: This review aims to answer important preclinical and clinical questions about the metabolism and physiological role of Lp(a) and also outlines possible therapeutic approaches with nutraceuticals, currently available lipid-lowering therapies and new medications. In addition, ways are illustrated to use Lp(a) as a marker to better predict cardiovascular risk.","PeriodicalId":10962,"journal":{"name":"Current Opinion in Clinical Nutrition and Metabolic Care","volume":" ","pages":"136-143"},"PeriodicalIF":3.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Clinical Nutrition and Metabolic Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MCO.0000000000000994","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Lp(a) is one of the most atherogenic lipoproteins, and significant progress has been made to understand its pathophysiology over the last 20 years. There are now selective therapies in late-stage clinical trials to lower Lp(a). Yet there are many outstanding questions about Lp(a). This review outlines 10 of the most burning questions and tries to answer some of them.

Recent findings: Antisense oligonucleotide (ASO) treatment is currently the most advanced therapy to lower plasma Lp(a) by 60-80%. There are, however, also two small molecule medications in early stage of development with similar efficacy.

Summary: This review aims to answer important preclinical and clinical questions about the metabolism and physiological role of Lp(a) and also outlines possible therapeutic approaches with nutraceuticals, currently available lipid-lowering therapies and new medications. In addition, ways are illustrated to use Lp(a) as a marker to better predict cardiovascular risk.

查看原文本刊更多论文

关于脂蛋白的10个基本问题(a)

综述目的:脂蛋白(a)是最易致动脉粥样硬化的脂蛋白之一，近20年来在了解其病理生理方面取得了重大进展。目前在后期临床试验中有选择性治疗降低Lp(a)。然而，关于Lp(a)还有许多悬而未决的问题。本文概述了10个最紧迫的问题，并试图回答其中的一些问题。反义寡核苷酸(ASO)治疗是目前最先进的降低血浆Lp(a) 60-80%的治疗方法。然而，也有两种小分子药物处于早期开发阶段，具有类似的疗效。摘要:本综述旨在回答关于Lp(a)的代谢和生理作用的重要临床前和临床问题，并概述了可能的营养药品治疗方法，目前可用的降脂疗法和新药。此外，还说明了使用Lp(a)作为标记物更好地预测心血管风险的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Clinical Nutrition and Metabolic Care 医学-内分泌学与代谢

CiteScore

5.30

自引率

6.50%

发文量

116

审稿时长

6-12 weeks

期刊介绍： A high impact review journal which boasts an international readership, Current Opinion in Clinical Nutrition and Metabolic Care offers a broad-based perspective on the most recent and exciting developments within the field of clinical nutrition and metabolic care. Published bimonthly, each issue features insightful editorials and high quality invited reviews covering two or three key disciplines which include protein, amino acid metabolism and therapy, lipid metabolism and therapy, nutrition and the intensive care unit and carbohydrates. Each discipline introduces world renowned guest editors to ensure the journal is at the forefront of knowledge development and delivers balanced, expert assessments of advances from the previous year.